Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
17 oct. 2023 16h00 HE
|
Recludix Pharma, Inc.
- Pioneering compounds believed to be the first orally administered reversible inhibitors to bind to and inhibit the SH2 domain potently and selectively - Proprietary STAT3 inhibitors are...
Recludix Pharma to Participate in Multiple Investor Conferences in September
30 août 2023 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
20 juil. 2023 08h00 HE
|
Recludix Pharma, Inc.
- Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales - - Recludix to lead research...
Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
01 févr. 2023 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
06 janv. 2023 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology
20 oct. 2022 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced...
Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer
29 sept. 2022 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
Recludix Pharma Announces the Appointment of Seasoned Biotech Leader Athena Countouriotis, M.D., as the Chairperson of the Board of Directors
13 sept. 2022 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
Recludix Pharma Announces Scientific Advisory Board
06 janv. 2022 08h00 HE
|
Recludix Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...